SOURCE: Alexion PharmaceuticalsDESCRIPTION:
As a leader in rare disease, it is our responsibility to lead critical conversations with stakeholders and other members of the rare disease community. Health equity is one of those conversations.
As a result of the ongoing global pandemic, the disparities in our healthcare systems have never been more obvious. The response to COVID-19 has proven that the talent, science, collaboration, and urgency needed to take on large global health crises exists. In the rare disease community, however, patient populations are small and spread out around the world and urgency is often lost. Yet with only five percent of rare diseases having an approved treatment option, the need for research, development, and delivery of new and effective treatment options is urgent. Because even though each rare disease may only impact a small number of people, the totality of those affected is hard to ignore with 400 million affected globally.
In support of Rare Disease Day’s focus on social equity and as part of Alexion’s Rare Inspiration. Changing Lives. speaker series, our Executive Vice President and Chief Corporate Affairs Officer, Tanisha Carino hosted a conversation with stakeholders from the rare disease community on the topic of health equity. We encourage you to visit Alexion’s Rare Disease Day microsite to hear what they had to say.
As advocates for the rare disease community, it is incumbent upon each of us to engage with, listen to, and give voice to those who rely on us. If the pandemic has taught us anything, it is that the louder the voice, the greater the urgency, and the more quickly we can find a solution.
To learn more about how Alexion is serving its communities, visit Alexion.com.
KEYWORDS: Alexion Pharmaceuticals, NASDAQ: ALXN